Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P820033/S017

Plasmaflo OP-05W(A)

Asahi Kasei Medical Co., Ltd. · Decision date Sep 30, 2025

FDA DECISIONP820033/S017

What did the FDA approve?

FDA records P820033/S017 as a supplement to PMA P820033, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 30, 2025.

FDA approval order statement

Your supplement requested approval for a change in the supplier of the lubricant, calcium stearate, added to the polyethylene resin used in the manufacture of the hollow fiber of the device.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Sep 30, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P820033/S017
Regulatory pathway
PMA supplement
Product code
MDP
Decision code
APPR
Decision date
Sep 30, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Separator for therapeutic purposes, membrane automated blood cell/plasma.

Product code
MDP
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P820033/S017 received

    Application receipt date recorded by FDA.

  2. P820033/S017 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P820033. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P820033

Product / regulatory recordCompanyPathwayDecision dateSource
Asahi Kasei Medical Co., Ltd.PMA supplementApr 9, 2026FDA

Explore the linked device profile

Other records with product code MDP

Product / regulatory recordCompanyPathwayDecision dateSource
Vantive US Healthcare, LLCPMA supplementJul 15, 2026FDA
Vantive US Healthcare, LLCPMA supplementMar 13, 2026FDA
Vantive US Healthcare, LLCPMA supplementDec 23, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Asahi Kasei Medical Co., Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1-105 Kanda Jinbocho, Chiyoda-Ku, Tokyo, 101-8101

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records